New Deals support novel Therapies and improved Assays
Aptamer, the developer of Optimer® binders with potential to open avenues of discovery for the life sciences industry, has announced a selection of new contract wins where its proprietary platform technology is being explored by partners to offer new strategies for therapeutics. Click to read more...
United Kingdom Arron Tolley Cancer Research United Kingdom Group Aptamer Chronic Myelomonocytic Leukaemia
Source: labmate-online.com